New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis

Japanese Journal of Clinical Immunology

Volumn 32, Issue 3, 2009, Pages 149-159

  Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Biologics; Inflammatory cytokine; Lymphocytes; Rheumatoid arthritis

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ADALIMUMAB; ATLIZUMAB; B CELL ACTIVATING FACTOR RECEPTOR; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; JANUS KINASE 3 INHIBITOR; METHOTREXATE; OCRELIZUMAB; OFATUMUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

B LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; JAPAN; MORTALITY; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 3; POLYETHYLENE GLYCOLS; PROTEIN-TYROSINE KINASES;

EID: 77953661085     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.32.149     Document Type: Review

References (17)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 46: 328-346, 2002.
2. Keystone E, Genovese MC, Klareskog L et al.: Golimumab, a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously every 4 weeks in patients with active rheumatoid arthritis despite methotrexate: week 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study. Ann Rheum Dis. 67(Suppl II):185, 2008 Dec 11. [Epub ahead of print]
3. Smolen J, Kay J, Doyle MK et al.: Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-controlled, GO-AFTER study. Ann Rheum Dis. 67(Suppl II):50, 2008.
4. Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58 (11): 3319-3329, 2008.
5. Genovese MC, Becker JC, Schiff M, et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114-1123, 2005.
6. Edwards JC et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004.
7. Emery P et al: Thee efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Result of phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400, 2006.
8. Cohen SB, Emery P, Greenwald MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks (REFLEX Randamized Evaluation of Long-term Efficacy of rituximab in RA) Arthritis Rheum. 54(9): 2793-2806, 2006.
9. Cohen S, Keystone E, Genovese MC et al.: Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX STUDY. Ann Rheum Dis 67(SupplII): 189, 2008.
10. Leandro MJ, et al.: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44: 1542-1545, 2005.
11. Tokunaga M, Fujii K, Saito K et al.: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44: 176-182, 2005.
12. Tanaka Y et al.: Rituximab reduces both quantity and quality of b cells in SLE. Rheumatology 45: 122-123, 2006.
13. Tokunaga M, Saito K, Kawabata D et al.: Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 66: 470-475, 2007.
14. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5: 197-209, 2006.
15. McClung MR, Lewiecki EM, Cohen SB, et al.: AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831, 2006
16. Kremer JM, Bloom BJ, Breedveld FC, et. al.: A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. [abstract] Arthritis Rheum 54 (suppl): S33, 2006.
17. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E.: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11): 3309-3318, 2008.